Emergent BioSolutions Inc. <EBS.N>: JP Morgan resumes coverage with Underweight rating
EBS•Related News
VinFast India partners with Federal Bank on dealer inventory financing
VFS•
Nektar Therapeutics <NKTR.O>: JPMorgan resumes coverage with neutral rating; target price $65
NKTR•
Corn retreats from 18-month high but heads for second weekly gain
DBA•
Treasury buyback renews dollar-debasement fears
TLT•
WISeKey appoints Alexander Hirsch as group chief marketing officer
WKEY•